Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDMEN: Methylprednisolone for Vertigo in Ménière's Disease
NCT05851508Phase 3Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2023
- Primary completion
- May 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Ménière's disease comparing Methylprednisolon with Placebo (2 arms). Primary endpoint: Vertigo spells at 1 year. Started Oct 2023; status: recruiting.
02
Drugs
methylprednisolone
03
Conditions
Ménière's disease
Beyond the preview
Go deeper on NCT05851508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05851508.